Related Experiment Videos
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT
Jeff Whittle1, Amy I Lynch2, Rikki M Tanner2
1Primary Care Division, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; jeffrey.whittle@va.gov.
Insights
Increased blood pressure variability is linked to higher kidney disease risk. This study found higher visit-to-visit blood pressure variability independently predicts worse renal outcomes.
Area of Science:
- Nephrology
- Cardiology
- Clinical Trials
Background:
- Visit-to-visit variability in blood pressure (BP) is a known risk factor for cardiovascular disease.
- Understanding its impact on renal outcomes is crucial for patient management.
Purpose of the Study:
- To investigate the association between visit-to-visit BP variability and the risk of renal outcomes.
- To analyze this association in a large cohort from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Main Methods:
- Utilized data from 21,245 participants in the ALLHAT trial.
- Measured mean BP and visit-to-visit BP variability (SD) over 5-7 visits.
- Defined composite renal outcome as incident end-stage renal disease (ESRD) or ≥50% eGFR decline.
Main Results:
- Higher quintiles of systolic BP variability (SD) were associated with increased risk of the composite renal endpoint (P trend =0.004).
- Hazard ratios increased progressively with higher SD of systolic BP, with the highest quintile showing a 2.05 HR.
- Similar associations were observed for ESRD and eGFR decline analyzed separately, and for diastolic BP variability.
Conclusions:
- Elevated visit-to-visit BP variability is an independent predictor of adverse renal outcomes.
- These findings highlight the importance of BP stability in preventing kidney disease progression.
Background And Objectives:
Increased visit-to-visit variability of BP is associated with cardiovascular disease risk. We examined the association of visit-to-visit variability of BP with renal outcomes among 21,245 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Design, Setting, Participants, & Measurements:
We measured mean BP and visit-to-visit variability of BP, defined as SD, across five to seven visits occurring 6-28 months after participants were randomized to chlorthalidone, amlodipine, or lisinopril. The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization. We repeated the analyses using average real variability and peak value of systolic BP and for visit-to-visit variability of diastolic BP.
Results:
Over a mean follow-up of 3.5 years, 297 outcomes occurred. After multivariable adjustment, including baseline eGFR and mean systolic BP, the hazard ratios for the composite end point were 1.29 (95% confidence interval [95% CI], 0.75 to 2.22), 1.76 (95% CI, 1.06 to 2.91), 1.46 (95% CI, 0.88 to 2.45), and 2.05 (95% CI, 1.25 to 3.36) for the second through fifth (SD of systolic BP =6.63-8.82, 8.83-11.14, 11.15-14.56, and >14.56 mmHg, respectively) versus the first (SD of systolic BP <6.63 mmHg) quintile of SD of systolic BP, respectively (P trend =0.004). The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP.
Conclusions:
Higher visit-to-visit variability of BP is associated with higher risk of renal outcomes independent of mean BP.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease I: Introduction
Hypertension and Regulation of Blood Pressure
Errors occurring during blood pressure monitoring
Several factors...
Chronic Kidney Disease IV: Nursing Management